STERIS (STE) to Release Quarterly Earnings on Wednesday

STERIS (NYSE:STE) is set to post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect STERIS to post earnings of $2.12 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

STERIS (NYSE:STE) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.16. The firm had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. STERIS’s revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.00 earnings per share. On average, analysts expect STERIS to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

STERIS Price Performance

Shares of NYSE STE opened at $225.82 on Tuesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. STERIS has a one year low of $195.47 and a one year high of $248.24. The firm has a market capitalization of $22.27 billion, a P/E ratio of 56.03 and a beta of 0.85. The company’s fifty day moving average is $233.54 and its two-hundred day moving average is $227.40.

STERIS Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $2.28 annualized dividend and a yield of 1.01%. STERIS’s payout ratio is currently 56.58%.

Insider Activity at STERIS

In related news, Director Christopher S. Holland sold 473 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now owns 582 shares of the company’s stock, valued at approximately $139,493.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. JMP Securities reissued a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research note on Wednesday, August 7th. Stephens restated an “overweight” rating and issued a $260.00 price target on shares of STERIS in a research report on Wednesday, August 7th. KeyCorp boosted their price objective on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Finally, Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and increased their price target for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $253.00.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.